Luís Moutinho | moutinho@ua.ptdose it well

CANCER the global Killer

1 in 3 peoplewill develop cancerduring their lifetimes

is the leading cause of death in the developed world

and 8 million deathsworldwide (2012)

14M new cases Prostate cancer4th cancer

with highest incidence1/3 are

prostate cancers

75%by 2030

is the leading cause of death in the developed world

1. The problem

1. The problem

surgery chemotherapytargeted therapy (hormone therapy, immunotherapy, gene therapy)

RT is one of the most e�cient treatments, however there’sno quality assurancein some modalities

radiotherapy (RT)

Dr. José Pérez CalatayudHead of Radiophysics in Radiotherapy Unit of Hospital La Fe de Valencia

1. The problem

there’s a need for in-vivo real-timedosimetry and real-time dose correction

2. radiation detection

they are too bulky, not flexible and not sensitive enoughcurrent solutions are not suitable for real-time in-vivo/in-situ dosimetry

real-time

low-energy

small size

in-vivo/in-situ

diodes diamondionizationchambers

MOSFET TLDinorganic organic

scintillators

3. Our product

Brachytherapyneedle

internal ø 1,067 mmexternal ø 1,473 mm

17G x 20 cm

dose it well

dose probe 1 :025 µGydose probe 2: 020 µGydose probe 3: acquiring

dose 334µGy

dosimeter for LDR and HDR brachytherapy

disposable probe allows insertion through standard brachyterapy needles

main unit (independent readout or with PC for dose correction)

- integration with planningsoftware for real time dose correction

- real time dose monitoring in sensitive organs

4. Our technology / uniqueness

Micropos MedicalRaypilot

ExradinW1 scintillator

Best Medical CanadaMosfet dosimeter

DRIM dose

(not in market)

Real-timedose correction

LDRbrachytherapy

HDRbrachytherapy

?

the only dosimeter capable to perform in-vivo and real time dose measurement at HDR and LDR regimes

5. Global market and segmentationis the leading cause of death in the developed worldprostate brachytherapy market

Dirac database

EuropeLatin America

Northern America 3388

645 1286

> 500 k patitents ongoing brachtytherapy without proper quality assurance!

7620 radiotherapy centers in the World:

SAM>300 M€

# of treatments per radiotherapy center: (average)

LDR: 60/year HDR: 100/year

!!!

6. Strategy / business model

key partners

key players

201524 - 28 April Barcelona, Spain

7. were we are

Business Idea Competition - prize Coimbra Inovação Parque | 1k€

1st place - Medical Devices & Health IT | 100k€

2012

Patent PT 106337 2013

2014

2015

LDR and HDR in-vitro trials

Interaction with key playersin the brachythreapy �eld

€ in-vivo tests:international IP:final prototype:

40 k€ (Portugal only)

55 k€ (markets of interest)

~150 k€

8. where we're headed / fundraising

€

in-vitro trialsLDR/HDR

in-vivo trialsLDR/HDR

Product certi�cation

fundraisingseries seed

9. revenue model

payback in the 2 year of salesnd

year of sales

dosimeterdisposable probes LDRdisposable probes HDRsoftware

Time-to-market 3 to 4 years

Revenue forecast€

Selling price estimated

8000 €115 €185 € -

JOÃO VELOSOPhD in Tech. Physics

Head of DRIM research group

I3N, University of Aveiro

LUÍS MOUTINHOM.Sc Biomedical devices

PhD student (Physics)

I3N, University of Aveiro

FILIPE CASTROPost-Doc

PhD in Physic Eng.

I3N, University of Aveiro

10. the team

CEO

dose it well

Luís Moutinho - moutinho@ua.pt

João Veloso - joao.veloso@ua.pt

Filipe Castro - ifcastro@ua.pt